Other languages Biofrontera Inc.

Equities

BFRI

US09077D2099

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-28 pm EDT			5-day change	1st Jan Change
1.05 ^USD	-0.01%		-5.84%	-62.10%

May. 16	Transcript : Biofrontera Inc., Q1 2024 Earnings Call, May 16, 2024
May. 15	Earnings Flash (BFRI) BIOFRONTERA Reports Q1 Revenue $7.9M, vs. Street Est of $10.9M	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Biofrontera Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15
Biofrontera Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 15
Biofrontera Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 15
Biofrontera Files Prospectus for Potential Secondary Stock Offerings	Mar. 11
Biofrontera Inc. Announces Restructuring of Supply Agreement with Biofrontera Ag	Feb. 20
MORNING BRIEFING - Deutschland/Europa -2-	Feb. 16
Biofrontera Inc. Announces FDA Filing of Supplemental New Drug Application for Ameluz(R) to Permit Up to Three Tubes Per Use	Feb. 05
Biofrontera Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2023	Jan. 11
Biofrontera Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09
Biofrontera Inc. Reaffirms Revenue Guidance for the Full Year 2023	Nov. 09
Biofrontera Licensor Gets FDA Approval for New Formulation of Ameluz to Treat Actinic Keratosis	23-10-10
Biofrontera Inc. Receives FDA Approval for New Formulation of Ameluz(R)	23-10-10
Biofrontera Inc. Provides Revenue Guidance for the Third Quarter and Nine Months of 2023 and Re-Affirms Revenue Guidance for the Year 2023	23-10-04
Biofrontera Inc. Appoints Samantha Widdicombe as Senior Director, Strategic Accounts and Communications	23-08-29
Biofrontera Says Skin Disease Therapy Was Well-Tolerated in Phase 1 Safety Trial	23-08-28
Biofrontera Inc. Announces Positive Results from Phase 1 Safety Study Evaluating Photodynamic Therapy with Three Tubes of Ameluz(R)	23-08-28
Biofrontera Inc. Affirms Guidance for 2023	23-08-11
Biofrontera Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11
Biofrontera Completes Patient Enrollment in Skin Cancer Treatment Study	23-08-10
Biofrontera Inc. Announces Last Patient Enrolled in Phase 3 Clinical Study Evaluating Ameluz(R)-Pdt for the Treatment of Basal Cell Carcinoma	23-08-10

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Biofrontera Inc.

Equities

BFRI

US09077D2099

Other languages

Filters